Cellectis (CLLS) Operating Income Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 12.69% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 75.16% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -347.04% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 80.62% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 1.27% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 8.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,386.07% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -77.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.49% |
| Dec 31, 2025 | -62.47% |
| Sep 30, 2025 | 174.67% |
| Jun 30, 2025 | 44.30% |
| Mar 31, 2025 | 32.14% |
| Dec 31, 2024 | 63.89% |
| Sep 30, 2024 | 47.90% |
| Jun 30, 2024 | 27.14% |
| Mar 31, 2024 | 10.83% |
| Dec 31, 2023 | -422.60% |
| Sep 30, 2023 | 24.43% |
| Jun 30, 2023 | 13.52% |
| Mar 31, 2023 | 19.83% |
| Dec 31, 2022 | 76.95% |
| Sep 30, 2022 | 35.44% |
| Jun 30, 2022 | 27.13% |
| Mar 31, 2022 | -46.82% |
| Dec 31, 2021 | 37.29% |
| Sep 30, 2021 | -44.34% |
| Jun 30, 2021 | -13.47% |
| Mar 31, 2021 | -238.13% |
| Dec 31, 2020 | -1.74% |
| Sep 30, 2020 | -10.14% |
| Jun 30, 2020 | 5.96% |
| Mar 31, 2020 | 162.34% |
| Dec 31, 2019 | -31.54% |
| Sep 30, 2019 | 7.79% |
| Jun 30, 2019 | -61.90% |
| Mar 31, 2019 | 7.16% |
| Dec 31, 2018 | -5.41% |
| Sep 30, 2018 | -12.45% |
| Jun 30, 2018 | -9.30% |
| Mar 31, 2018 | -26.11% |
| Dec 31, 2017 | -36.60% |
| Sep 30, 2017 | -99.25% |
| Jun 30, 2017 | -75.37% |
| Mar 31, 2017 | 12.28% |
| Dec 31, 2016 | -1,636.11% |
| Sep 30, 2016 | 13.75% |
| Jun 30, 2016 | 15.54% |
| Mar 31, 2016 | -459.99% |